title: Hilar cholangiocarcinoma.
abstract: Hilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the different series currently range from 25% to 45%. A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in a special issue.
authors.affiliation: José M Ramia, Department of Surgery, Hospital Universitario de Guadalajara, 19002 Guadalajara, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Ramia
keywords: Cancer; Cholangiocarcinoma; Hilar; Klatskin; Perihilar; Review; Surgery
references.citation: Arch Surg. 2012 Jan;147(1):26-34
references.pmid: 22250108
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):139-46
references.pmid: 23919108
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):147-58
references.pmid: 23919109
references.citation: Cancer. 2012 Oct 1;118(19):4737-47
references.pmid: 22415526
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):171-6
references.pmid: 23919111
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):132-8
references.pmid: 23919107
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):127-31
references.pmid: 23919106
references.citation: Br J Surg. 2012 Jul;99(7):885-6
references.pmid: 22556154
references.citation: Ann Surg. 2013 Jul;258(1):129-40
references.pmid: 23059502
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):159-70
references.pmid: 23919110
references.citation: World J Gastrointest Oncol. 2013 Jul 15;5(7):115-26
references.pmid: 23919105